Profilo
David Hyman has worked as a Chief Medical Officer at Eli Lilly & Co. since 2023 and at Loxo Oncology, Inc. since 2020.
Posizioni attive di David Hyman
| Società | Posizione | Inizio |
|---|---|---|
| LOXO ONCOLOGY INC | Chief Tech/Sci/R&D Officer | 01/01/2020 |
| ELI LILLY AND COMPANY | Chief Tech/Sci/R&D Officer | 16/10/2023 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
52
Relazioni di 1° grado
2
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| Aziende private | 1 |
|---|---|
Loxo Oncology, Inc.
 Loxo Oncology, Inc. Pharmaceuticals: MajorHealth Technology Loxo Oncology, Inc. is a biopharmaceutical company, which engages in the development of small molecule therapeutics for the treatment of cancer. It focuses on genetic alterations, targeted therapies, and genetic testing. The company was founded by Joshua H. Bilenker in May 2013 and is headquartered in Stamford, CT. | Health Technology |
- Borsa valori
- Insiders
- David Hyman
